•  
  •  
  •  
  •  

2025-09-01 00:48:32

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism

Keywords Selected:  USFDA

Stock Report

  • Apitoria Pharma Pvt Ltd receives 5 observations from USFDA for API facility
  • SMS Pharmaceuticals Ltd receives EIR from USFDA for Central Laboratory Analytical Services
  • Unichem Laboratories Ltd receives EIR from USFDA classifying Roha API facility as VAI
  • Gland Pharma receives approval for Vasopressin in 5% Dextrose RTU Injection
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg
  • Gland Pharma receives approval for Norepinephrine Bitartrate in 5% Dextrose Injection Bags
  • Gland Pharma receives approval from USFDA for Cangrelor for Injection 50 mg/vial
  • Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg
  • Senores Pharmaceuticals Ltd's material subsidiary reeceives 3 observations from USFDA for its facility
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg
  • Lupin receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
  • Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
  • Lupin receives Form 483 with 3 observations from USFDA for Pithampur Unit-3
  • Lupin receives Form 483 with 4 observations from USFDA for Pithampur Unit-2
  • EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg
  • Emcure Pharmaceuticals Ltd successfully completes USFDA PAI of Oncology facility
  • Lupin receives approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Neuland Laboratories Ltd receives EIR from USFDA for Unit 2 at Pashamylaram Village
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • J.B. Chemicals & Pharmaceuticals Ltd receives USFDA approval for ANDA Amitriptyline Hydrochloride Tablets

Latest Post

  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024